Date: 2016-03-14
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 14th International Symposium on Advances in Alzheimer’s Therapy (AAT)
Company: Anavex Life Sciences (USA - NY)
Product: ANAVEX 3-71 - 1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one
Action
mechanism: ANAVEX 3-71 (previously AF710B) is a preclinical drug candidate targeting both sigma-1 and M1 muscarinic receptors demonstrating neuroprotection and improved cognition in Alzheimer’s disease models. It is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with potential disease modifications. ANAVEX 3-71 is effective in very low doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and has also demonstrated beneficial effects on neuroinflammation and mitochondrial dysfunctions.
Disease: Alzheimer's disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On March 14, 2016, Anavex Life Sciences announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. The poster, titled “AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats,” was presented at the 14th International Symposium on Advances in Alzheimer’s Therapy (AAT) from March 9-12, 2016. The study examined the responses of ANAVEX 3-71 in aged transgenic McGill-R-Thy1-APP rats and wild-type rats dosed with 10 micrograms/kg/day ANAVEX 3-71. Both types of rats (12-14 months of age) were given either oral ANAVEX 3-71 or a placebo control for 4.5 months and then subjected to a washout period for five weeks. Following the washout, a number of cognitive tests were performed with the rats, now 18-20 months of age.
Despite the treatment interruption, the effects of administration of ANAVEX 3-71 resulted in a statistically significant improvement in cognitive function assessed by Novel Object Recognition and Morris Water Maze. In the Novel Object Recognition task, ANAVEX 3-71 completely reversed the deficit observed in transgenic rats (p<0.001), which performed similarly to wild-type rats. In the Morris Water Maze task, treated transgenic rats also fully recovered to perform at a level comparable to that of wild-type rats (p<0.001). A statistically significant reduction (p<0.05) in two measures of amyloid-beta pathology commonly associated with Alzheimer’s disease was also observed in comparison to control. Additionally, ANAVEX 3-71 demonstrated anti-inflammatory properties, compared to control (p<0.05), which may also have relevance in Alzheimer’s disease.
